No Detail Found!

Discovery of Potent analogue of Isoflavone Genistein as Monoamine Oxidase-B Inhibitors by in-silico Approach

Author(s)
Mahwish Akhtar Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi-Pakistan.
Afia Abdullah Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi-Pakistan.
Sabahat Naeem Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi-Pakistan.
Noor Jahan Department of Pharmacology, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi-Pakistan.
Faisal Mohammad Khan Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi-Pakistan.
Syeda Kiran Federal Urdu University of Arts Science and Technology, Pakistan.
Moona Mehboob Khan Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi-Pakistan.
Abstract
Aim and Objectives: The aim of this research study is to find the MAO-B inhibitors for the treatment of Parkinson's disease using in-silico approaches. Background: Parkinson's disease (PD) is a degenerative disorder of CNS, characterized by cerebral depletion of dopamine (DA), Monoamine oxidases (MAO) carry out the oxidative deamination of monoamines like DA. Hence, one of the approaches to delay the depletion of DA is to inhibit its oxidative deamination. Material and methods: Genistein, a potent inhibitor of MAO-B was selected form literature and a library of 40% similar compounds was downloaded using ZINC databases. The binding potency (?G) of generated library of 30 compounds was analyzed by docking using AutoDock-Vina. The results were compared with both the parent and the standards Luteolin and Selegiline. The top 7 compounds with excellent binding energies were further investigated for drug-likeness physico-chemical, pharmacokinetics and toxicological parameters via SwissADME. Results: It was observed that ?G values of almost all the compounds were better than parent Genistein and seligiline and 7 compounds demonstrated binding energies better than and equal to the Luteolin, among them, compound 15 showed the least ?G of -10 Kcal/mol. The selected compounds were also qualified for all drug-likeness, physicochemical, pharmacokinetics, and toxicological parameters. Conclusion: The in-silico findings concluded that all selected compounds had the potential to interact with MAO-B, compound 15 with the least binding energy, good pharmacokinetics and low toxicity evolved out as the most potent inhibitor of MAO-B and hence could be offered for further drug development process.
Publication Details
Page(s) 1-15
DOI DOI not available
Published Journal: RADS Journal of Pharmacy and Allied Health Sciences, Volume: 2, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
isoflavone, molecular docking, MAO inhibitor, Genistein, Parkinson's disease
References
Dorsey E,Sherer T,Okun MS,Bloem BR .2018 .The emerging evidence of the Parkinson pandemic. J Parkinsons Dis, 8(s1) : .
Vos T,Allen C,Arora M,Barber RM,Bhutta ZA,Brown A .2016 .The Lancet. , 388(10053) : 1545-602.
Lotharius J,Brundin P .2002 .Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci, 3(12) : 932-42.
Kouli A,Torsney KM,Kuan W .2018 .Parkinson's disease: etiology, neuropathology, and pathogenesis. Exon Publications, : 3-26.
Sivaraman D,Srikanth J .2016 .Discovery of novel monoamine oxidase-B inhibitors by molecular docking approach for Alzheimer's and Parkinson's disease Treatment. Int J Pharm Sci Rev Res, 40(1) : 245-50.
Westlund K,Denney R,Rose R,Abell C .1988 .Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neurosci, 25(2) : 439-56.
Edmondson D,Mattevi A,Binda C,Li M,Hubalek F .2004 .Structure and mechanism of monoamine oxidase. Curr Med Chem, 11(15) : 1983-93.
Nicotra A,Pierucci F,Parvez H,Senatori O .2004 .Monoamine oxidase expression during development and aging. Neurotoxicology, 25(1-2) : 155-65.
Dezsi L,Vecsei L .2017 .Monoamine oxidase B inhibitors in Parkinson's disease. CNS Neurol Disord Drug Targets, 16(4) : 425-39.
Lecht S,Haroutiunian S,Hoffman A,Lazarovici P .2007 .Rasagiline-a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag, 3(3) : 467-74.
Riederer P,Müller T. .2018 .Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: Clinical-pharmacological aspects. J Neural Transm, 125 : 1751-7.
Pinzi L,Rastelli G.,Molecular G. .2019 .Docking: Shifting Paradigms in Drug Discovery. Int J Mol Sci, 20(18) : 4331.
Sethi A,Joshi K,Sasikala K,Alvala M.,Gaitonde V,Karmakar P,Trivedi A . .Molecular docking in modern drug discovery: Principles and recent applications. United Kingdom: IntechOpen; 2019, : 21-47.
Kumar S,Pandey AK .2013 .Chemistry and biological activities of flavonoids: an overview. The Scientific World Journal, : .
Yanagihara N,Zhang H,Toyohira Y,Takahashi K,Ueno S,Tsutsui M .2014 .New insights into the pharmacological potential of plant flavonoids in the catecholamine system. Journal of Pharmacological Sciences, 124(2) : 123-8.
Han XH,Hong SS,Hwang JS,Lee MK,Hwang BY,Ro JS .2007 .Monoamine oxidase inhibitory components from Cayratia japonica. Arch Pharm Res, 30(1) : 13-7.
Kumar S,Ayyannan SR .2022 .Identification of new small molecule monoamine oxidase-B inhibitors through pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation studies. J Biomol Struct Dyn, : 1-22.
Abdelgawad MA,Oh JM,Parambi DG,Kumar S,Musa A,Ghoneim MM .2022 .Development of bromo-and fluoro-based α, β-unsaturated ketones as highly potent MAO-B inhibitors for the treatment of Parkinson's disease. J Mol Struct, 1266 : 133545.
Soufi W,Merad M,Hacene FB,Ghalem S. . .Study of Monoamine Oxidase-B and Indole Derivatives Using Two Molecular Docking Programs: Molegro and MOE. , : .
Kong LD,Tan RX,Woo AY,Cheng CH .2001 .Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol, 88(2) : 75-80.
Booth NL,Overk CR,Yao P,Burdette JE,Nikolic D,Chen SN .2006 .The chemical and biologic profile of a red clover (Trifolium pratense L.) phase II clinical extract. J Altern Complement Med, 12(2) : 133-9.
Sharma K. Chromone .2022 .Scaffolds in the Treatment of Alzheimer's and Parkinson's Disease: An Overview. ChemistrySelect, 7(18) : .
Seong SH,Kim BR,Cho ML,Kim TS,Im S,Han S .2022 .Phytoestrogen Coumestrol Selectively Inhibits Monoamine Oxidase-A and Amyloid β Self-Aggregation. Nutrients, 14(18) : 3822.
Das T,Saha SC,Sunita K,Majumder M,Ghorai M,Mane AB .2022 .Promising botanical-derived monoamine oxidase (MAO) inhibitors: Pharmacological aspects and structure-activity studies. S Afr J Bot, 146 : 127-45.
Musa A,Della Grace Thomas Parambi MS,Alshammari RB,Abdelgawad MA,Sundar D,Panda MKS .2022 .In Silico Approaches to Naturally Existing Chalcones and Flavonoids on Mao Inhibitory Action: A Boon to CNS Drug Discovery. In: Flavonoids and Phenolics, : 173-95.
Mahnashi MH,Ayaz M,Ghufran M,Almazni IA,Alqahtani O,Alyami BA .2023 .Phytochemicals-based β-amyloid cleaving enzyme-1 and MAO-B inhibitors for the treatment of Alzheimer's disease: molecular simulations-based predictions. J Biomol Struct Dyn, : 1-13.
Liu LX,Chen WF,Xie JX,Wong MS .2008 .Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci Res, 60(2) : 156-61.
Irwin JJ,Sterling T,Mysinger MM,Bolstad ES,Coleman RG .2012 .ZINC: a free tool to discover chemistry for biology. J Chem Inf Model, 52(7) : 1757-68.
Biovia DS .2017 .Discovery studio modeling environment. Release, : .
Trott O,Olson AJ .2010 .AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem, 31(2) : 455-61.
DeLano WL .2002 .The PyMOL molecular graphics system. , : .
Daina A,Michielin O,Zoete V. .2017 .SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep, 7(1) : 42717.
Pires DE,Blundell TL,Ascher DB .2015 .pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem, 58(9) : 4066-72.
Walters WP .2012 .Going further than Lipinski's rule in drug design. Expert Opin Drug Discov, 7(2) : 99-107.
Saeed A,Rehman S,Channar PA,Larik FA,Abbas Q,Hassan M .2017 .Long chain 1-acyl3-arylthioureas as jack bean urease inhibitors, synthesis, kinetic mechanism and molecular docking studies. J Taiwan Inst Chem Eng, 77 : 54-63.
Hecht D,Fogel GB .2009 .Computational intelligence methods for ADMET prediction. Front Drug Des Discov, 4(27) : 351-77.
Hosea NA,Jones HM .2013 .Predicting pharmacokinetic profiles using in silico derived parameters. Mol Pharm, 10(4) : 1207-15.
Hardjono S,Siswandono S,Andayani R .2018 .Evaluation of N-benzoylthiourea derivatives as possible analgesic agents by predicting their physicochemical and pharmacokinetic properties, toxicity, and analgesic activity. Indones J Biotechnol, 22(2) : 76-85.
Hu YQ,Fan J,Song XF,Vitro In,‐ In .2018 .‐methylenetethered Isatin‐moxifloxacin Hybrids. J Heterocycl Chem, 55(1) : 246-50.
Xu Z,Song XF,Fan J,Lv ZS,‐ ZS .2018 .‐ methylene‐tethered (Thio) semicarbazoneisatin‐moxifloxacin Hybrids. J Heterocycl Chem, 55(1) : 77-82.
Drusano G,Standiford H,Plaisance K,Forrest A,Leslie J,Caldwell J .1986 .Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother, 30(3) : 444-6.
Moroy G,Martiny VY,Vayer P,Villoutreix BO,Miteva MA .2012 .Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov Today, 17(1-2) : 44-55.
0

Citations

0

Downloads

11

Views